Evidence map›Paper›PMID 42618930›Full record

ArticleRadiation oncology (London, England)2026

Clinical and prognostic insights into radiation-associated angiosarcoma: a multi-institutional analysis.

Melissa Harbrücker, Sebastian Hoffmann, Johannes Tobias Thiel, Noelle Samira Jacob-Rehfeld, Sebastian M Christ, Adrien Daigeler, Anna Duprée, Felix Ehret, Anne Flörcken, Peter Hohenberger and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Melissa Harbrücker *Surgical Clinic, Faculty of Medicine Mannheim, University Medicine Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. Melissa.Harbruecker@umm.de.
Sebastian Hoffmann *Department of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tübingen, University of Tübingen, Schnarrenbergstraße 95, 72076, Tübingen, Germany.
Johannes Tobias ThielDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tübingen, University of Tübingen, Schnarrenbergstraße 95, 72076, Tübingen, Germany.
Noelle Samira Jacob-RehfeldDepartment of Internal Medicine II, Oncology/Hematology/BMT/Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sebastian M ChristDepartment of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
Adrien DaigelerDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Trauma Center Tübingen, University of Tübingen, Schnarrenbergstraße 95, 72076, Tübingen, Germany.
Anna DupréeDepartment of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Felix EhretCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Augustenburger Platz 1, 13353, Berlin, Germany.
Anne FlörckenCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany.
Peter HohenbergerDivision of Surgical Oncology and Thoracic Surgery, University Medical Center Mannheim, Medical Faculty Mannheim - Heidelberg University, Heidelberg, Germany.
Bernd KasperSarcoma Unit, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC), Mannheim, Germany.
Christoph ReißfelderSurgical Clinic, Faculty of Medicine Mannheim, University Medicine Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Jens JakobSurgical Clinic, Faculty of Medicine Mannheim, University Medicine Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Ulrich KneserDepartment of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Trauma Center, BG Trauma Center Ludwigshafen, University of Heidelberg, 67071, Ludwigshafen, Germany.
Felix StrübingDepartment of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Trauma Center, BG Trauma Center Ludwigshafen, University of Heidelberg, 67071, Ludwigshafen, Germany.
Jana Käthe Striefler *Department of Internal Medicine II, Oncology/Hematology/BMT/Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Siyer Roohani *Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Augustenburger Platz 1, 13353, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate oncological outcomes and prognostic factors in patients with radiation-associated angiosarcoma (RAAS) treated at referral centers.

methodsWe conducted a multi-institutional retrospective cohort study of patients with histopathologically confirmed primary or recurrent RAAS treated at four referral centers in Germany. Endpoints were overall survival (OS) and progression-free survival (PFS), estimated using the Kaplan-Meier method. Prognostic factors were assessed using multivariable Cox regression.

resultsAmong 71 patients (97.2% female; median age 69 years), 90% had a history of breast cancer treated with radiotherapy (RT). RAAS developed after a mean latency of 7 years, with a median RT dose of 59.4 Gy. Over a median follow-up of 13.0 months, OS reached a median of 41.7 months, with 1- and 2-year rates of 82.9% and 61.7%, respectively. Median PFS was 9.5 months, with 1- and 2-year rates of 43.7% and 27.1%. Larger tumor size (HR 1.09, p = 0.032) and metastatic disease at diagnosis (HR 2.98, p = 0.003) were associated with worse OS.

conclusionsRAAS are aggressive, frequently relapsing malignancies occurring years after RT. Larger tumor size and metastatic presentation are associated with worse OS. Multi-institutional and translational studies are needed to clarify disease biology, refine risk factors, and guide treatment strategies.

Indexed as

HemangiosarcomaNeoplasms, Radiation-InducedAdultAgedAged, 80 and overBreast NeoplasmsFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateBreast cancerCancer survivorshipSecondary malignancySoft tissue sarcomaToxicity

Identifiers

PMID42618930
PMCPMC13488017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.